You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News and reporting on melanoma.
In the upcoming clinical trial, the companies will evaluate the effects of IDEAYA's PKC inhibitor IDE196 and Pfizer's MEK inhibitor binimetinib.
The study will evaluate the effects of investigational drug IN10018 as a monotherapy and in combination with a MEK inhibitor.
Overexpression of immunoproteasome components PSMB8 and PSMB9 were found to be predictive of improved survival and response to immunotherapy.
Researchers have identified immune cell gene expression signatures that could one day be developed into tests to predict response to treatment.
Assessing T cell fraction alongside tumor thickness was superior to other histopathological variables for accurate progression-free survival prediction.
Three new studies have found that the presence of B cells in tertiary lymphoid structures in tumors is associated with a favorable response to immunotherapy.
Researchers tested the combined treatment in mice, after detecting increased PAK4 expression and reduced immune infiltration in melanoma patients with poor anti-PD-1 response.
The company will soon start discussing registrational studies with the FDA and will report 36-month survival data in mid-2020.
More individuals treated with BRAF- and MEK-targeted drugs were still alive after four years than would be expected with conventional chemo drugs.
Researchers have shown that the use of antibiotics in the weeks leading up to immunotherapy may lessen a patients' response to the treatment.